

C10
Cancu

the FVIII Intron 1 and Intron 12 locations led to a 100 times higher intracellular production than all other constructs and a 9 times higher secretion of the protein. This improved production and secretion was observed in two different cell lines: CHO and HepG2 cells. The FVIII produced was fully active on a one stage clotting assay and appears homogenous on immunoblot. The mRNA amount of all the constructs tested differs no more than three times indicating that the benefit observed in the production is coming both from a transcriptional and a translational effect.--

IN THE CLAIMS:

Please amend claims 7, 8 and 11 as follows:

- Sub
E1
C11
7. **(Amended)** A process for the production of Factor VIII protein comprising:
- a) preparing a modified Factor VIII cDNA, wherein said Factor VIII cDNA is modified by deletion of the B-domain and an insertion of the truncated Factor XI intron 1 (SEQ. ID NO: 9) in one or more splice sites of the Factor VIII cDNA;
 - b) introducing the modified Factor VIII cDNA into a cell; and
 - c) expressing the modified cDNA in said cell to produce Factor VIII protein.
8. **(Amended)** A process for the production of Factor VIII protein comprising:
- a) preparing a modified Factor VIII cDNA, wherein said Factor VIII cDNA is modified by replacement of the B-domain with nucleotides encoding four

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com